Updated:
Neuronetics
Neuronetics sells the FDA-cleared NeuroStar TMS system, treating major depressive disorder in outpatient psychiatric clinics across the United States.
Neuronetics
Neuronetics was founded in 2003 and received its first FDA clearance for NeuroStar in 2008, opening a new reimbursement pathway in the psychiatric services market. The company designs and distributes a transcranial magnetic stimulation (TMS) system that delivers targeted magnetic pulses to the brain's prefrontal cortex. The primary clinical indication is major depressive disorder (MDD) in adults who have not responded to at least one antidepressant medication. The company's business model pairs device sales with a per-treatment, recurring revenue stream through its TrakStar Patient Data Management System (per the firm's annual report, 2022). The firm's deployment is concentrated in a single asset class: neuromodulation hardware and related clinical services for mental health. Positions are physical device installs — NeuroStar units sold into outpatient psychiatric practices, hospitals, and U.S. Veterans Affairs facilities, or placed under operating leases. Geographic footprint is overwhelmingly the United States, with expansion into Japan through a distribution agreement with Teijin Pharma (per the firm's SEC filings, 2020). The company competes against medical device makers like BrainsWay, which markets a deep TMS system with a different coil design and additional FDA-cleared indications. Keith J. Sullivan has led the company as CEO since 2019 after serving as Chief Commercial Officer. Neuronetics trades on NASDAQ under the symbol STIM. The company's headcount and manufacturing relationships are centered at its Malvern, Pennsylvania headquarters. In November 2023, Neuronetics announced a strategic restructuring that included a workforce reduction of roughly 15% to lower operating expenses and target a path to cash-flow break-even (per the firm's 8-K filing, November 2023). Neuronetics occupies a structurally distinct position: it is an asset-heavy operating company that owns a capital-sales channel into independent psychiatric offices, wrapped around a proprietary CPT code (90867) for TMS treatment. The company's durability depends not on drug pipelines or clinical trial phases, but on insurance coverage momentum — with Medicare, UnitedHealthcare, Anthem, and other large payors maintaining medical policies that reimburse NeuroStar-delivered TMS for treatment-resistant depression.
General information
Firm type
Asset Manager
Year founded
2003
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Malvern
Corporate office
Malvern, PA, United States
Principals
Keith J. Sullivan
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is Neuronetics' core product, and what does the FDA clearance cover?
The core product is NeuroStar, a transcranial magnetic stimulation (TMS) device. The FDA cleared it in 2008 for the treatment of major depressive disorder in adults who have not achieved satisfactory improvement from prior antidepressant medication. In 2018, the agency cleared an advance-model NeuroStar system with an improved user interface and touchscreen controls, but the primary clinical indication remained MDD (per the firm's SEC filings).
How does the company generate recurring revenue?
Beside the initial hardware sale, Neuronetics captures per-treatment economics. Each NeuroStar unit ships with the TrakStar Patient Data Management System, which allows clinicians to manage patient sessions. The recurring revenue stream — labeled 'treatment session sales' in SEC filings — comes from the purchase of proprietary single-use treatment cartridges required to deliver each magnetic pulse session. This is a razor-and-blade model attached to a clinical workflow.
Who are Neuronetics' direct competitors in the TMS market?
The primary listed competitor is BrainsWay, which markets a deep TMS system using a patented H-coil and holds FDA clearances for MDD, obsessive-compulsive disorder, and smoking cessation. Magstim and MagVenture also offer TMS devices cleared for MDD. Each competitor varies in coil design, depth of magnetic penetration, and reimbursement coverage profile.
What insurance coverage exists for NeuroStar treatments?
NeuroStar treatments are billed under CPT code 90867 for TMS. Major commercial payers including UnitedHealthcare, Anthem, Cigna, Aetna, and many Blue Cross Blue Shield plans publish coverage policies for TMS when specific prior-authorization criteria are met. Medicare provides coverage in most regions for treatment-resistant MDD, which Neuronetics has repeatedly cited as a material tailwind in its investor communications.
Is Neuronetics an investment firm managing a pool of third-party capital?
No. It is a publicly traded medical technology company that sells medical devices and consumables to healthcare providers. It should not be classified as a family office, venture capital fund, or asset manager. Any profile treating it as an investment firm reflects a classification error.
What does the recent November 2023 restructuring signal about the company's operating posture?
The restructuring announced in November 2023 reduced headcount by roughly 15% and was framed by management as a reorganization to lower break-even costs. This signals a transition from growth-focused investment toward a leaner operating model focused on cash-flow generation, likely in response to elevated capital costs and cost-of-living pressures on outpatient psychiatric volumes (per the firm's 8-K filing, November 2023).
Does the company have exposure outside the United States?
Neuronetics reported a distribution partnership with Teijin Pharma Limited for the Japanese market, where TMS received regulatory clearance for MDD. Beyond that arrangement, international revenue has not been a material disclosed driver in its SEC filings. The installed base and treatment-session revenue remain overwhelmingly concentrated in the United States.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: